Navigation Links
BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors
Date:2/5/2008

BURLINGAME, Calif., Feb. 5 /PRNewswire/ -- BioSeek, Inc. today announced that Roy A. Whitfield has been elected executive chairman of the Company's board of directors. Mr. Whitfield had joined BioSeek's board of directors and served as a business advisor to the Company since November, 2005.

"Roy's management experience and expertise in drug discovery and business development have been extraordinarily valuable to BioSeek thus far. We look forward to his continued leadership and guidance as executive chairman as we advance our internal drug discovery and development efforts and continue to secure corporate partnerships that capitalize upon our BioMAP(R) screening systems platform," said Michael C. Venuti, Ph.D., CEO of BioSeek.

Roy Whitfield has over 20 years of management and governance experience in the biotechnology industry. Most recently, Roy served as CEO and Chairman of Incyte Corporation, a genomics company he co-founded in 1991. Incyte pioneered the commercialization of high throughput and information technology in pharmaceutical and medical research. At Incyte, Roy executed the first genomics initial public offering (IPO) and later raised over $700 million in financing. In 1997, he was named Northern California "Entrepreneur of the Year" for Life Sciences. Roy also serves on the boards of directors of Incyte Corporation, Nektar Therapeutics, Illumina and several private companies, and in the past served on the boards of Aurora Biosciences and the Biotechnology Industry Organization (BIO). Roy received a B.A. degree from Oxford University and an M.B.A. from Stanford University.

About BioSeek

BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications.

For more information, go to http://www.bioseekinc.com

BioSeek Contacts:

BioSeek, Inc.

Michael Venuti, Ph.D.

CEO

Tel: 650.552.0754

MacDougall Biomedical Communications

Jennifer Greenleaf

Tel: 781.235.3060


'/>"/>
SOURCE BioSeek, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProCure Selects IMPAC as Provider of Oncology Information Systems
2. Association of Clinical Research Organizations (ACRO) Elects New Officers for 2008
3. GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
4. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
5. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
6. GeneSeek Selects the British Midlands as Base for New UK/European Operations
7. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. E-Rad Solutions Selects Compressus Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market
10. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
11. Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... 2017 , ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, ... . GGI's mission is to advance global health and highlight the greater good of ... of each clinical trial volunteer. The vision of GGI is to serve as a ...
Breaking Biology Technology:
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):